Given the need in Latin America to have independence to face future pandemics, and having as a priority the care of life, VaxThera is born, a SURA company, expert in research, development and innovation of biologics, which will allow the production, importation and commercialization of vaccines in Colombia and the region.

This company has a projected investment of US$54 million by Seguros SURA Colombia for the first phase and the knowledge of a group of researchers, led by Jorge Emilio Osorio Benítez, PhD, with more than 30 years of experience in the research and development of vaccines.

VaxThera will allow importing and commercializing vaccines and other types of biologicals for Colombia and Latin America, as well as transferring the necessary technology to the country to produce and develop this type of products, thus contributing to the health security of the country and the region.

"Different world institutions and health experts have repeatedly warned that the world must prepare for future pandemics, in order to deploy all human, technological and logistical capabilities to protect populations. Aware of this situation and seeking to protect life, at Seguros SURA we decided to invest in the creation of VaxThera, since this articulation will allow us to advance in biotechnology, as well as to develop and strengthen capacities that will turn Colombia into a determining factor for Latin America. At SURA we believe in the importance of research, development and innovation at the service of people", commented Juan David Escobar, President of Seguros SURA Colombia.

The Company is currently developing a universal vaccine against the coronavirus, which is in the pre-clinical testing phase in Wisconsin (United States) and it is expected to be ready by 2023; it will serve as a booster vaccine, which will facilitate procurement and distribution processes.

VaxThera will also have the capacity to research and produce vaccines against dengue, chikungunya, yellow fever, influenza and Zika. While this development materializes, progress will be made in importing several types of vaccines needed in the region together with strategic allies, both for coronaviruses and other types of tropical diseases, in order to provide the population with timely access to these drugs and contribute to health security in Latin America.

VaxThera will represent a sustainable advance in terms of biotechnology and development of specialized skills and human talent, seeking for Colombia to become a major player in research, development and innovation, which will translate into technological and biological improvements at the service of the health of Colombians and Latin Americans.